Molidustat (BAY85-3934): HIF-PH Inhibitor for Renal Anemia & Oxygen Sensing

Executive Summary: Molidustat (BAY85-3934) is a selective inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PH) with IC₅₀ values of 480 nM (PHD1), 280 nM (PHD2), and 450 nM (PHD3) under standard in vitro conditions (APExBIO). Its activity stabilizes HIF-1α, resulting in increased erythropoietin (EPO) synthesis and correction of anemia in chronic kidney disease (CKD) models (Wu et al. 2020, DOI). The efficacy of Molidustat is inversely related to 2-oxoglutarate concentrations but is minimally affected by Fe²⁺ and ascorbate levels (America Peptide, 2023). In vivo, repeated dosing elevates hemoglobin without excessive EPO or hypertensive effects, unlike recombinant EPO therapy (SM-102.com). Clinical trials are evaluating its therapeutic value in CKD-associated anemia (APExBIO).

Biological Rationale

The oxygen sensing pathway is central to erythropoiesis and cellular adaptation to hypoxia. Under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylase domain (PHD) enzymes, leading to its ubiquitination and degradation by the von Hippel-Lindau (VHL) E3 ligase complex (Wu et al. 2020, DOI). Disruption of this pathway, such as in CKD, reduces EPO expression and causes anemia. Stabilizing HIF-1α via HIF-PH inhibition increases EPO production and improves red blood cell counts, providing a mechanistic rationale for pharmacological intervention (SM-102.com). Molidustat directly targets this oxygen-sensing checkpoint by inhibiting PHD isoforms, leading to controlled activation of hypoxia-responsive genes.

Mechanism of Action of Molidustat (BAY85-3934)

Molidustat (SKU B5861) is a small-molecule inhibitor with selective activity against PHD1, PHD2, and PHD3. By occupying the 2-oxoglutarate binding site, it prevents prolyl hydroxylation of HIF-1α, blocking VHL-mediated ubiquitination and proteasomal degradation (Wu et al. 2020). This stabilization increases HIF-1α nuclear translocation and transcriptional activation of EPO and other hypoxia-responsive genes. In vitro, Molidustat’s potency is higher at low 2-oxoglutarate concentrations but is relatively insensitive to variations in Fe²⁺ and ascorbate. In vivo, the compound normalizes hemoglobin and blood pressure in renal anemia models without causing supraphysiological EPO levels, differentiating it from exogenous EPO treatments (SM-102.com).

Evidence & Benchmarks

• Molidustat inhibits PHD1, PHD2, and PHD3 with IC₅₀ values of 480 nM, 280 nM, and 450 nM, respectively, in cell-free assays at 37°C, pH 7.4 (APExBIO).
• HIF-1α stabilization by Molidustat leads to upregulation of EPO gene expression and red blood cell production in CKD models (Wu et al. 2020, DOI).
• In rat studies, repeated oral dosing increased hemoglobin to physiological range (14–16 g/dL) without excessive EPO elevation or hypertension (SM-102.com).
• The compound’s efficacy is enhanced at lower 2-oxoglutarate concentrations but is unaffected by Fe²⁺ and ascorbate variation (America Peptide).
• Molidustat is insoluble in water/ethanol but dissolves in DMF at ≥5.68 mg/mL at room temperature (APExBIO).

Applications, Limits & Misconceptions

Molidustat is indicated for use in preclinical and clinical studies of renal anemia and hypoxia signaling. Its selectivity for HIF-PH isoforms enables precision modeling of oxygen sensing and EPO regulation. Compared to recombinant human EPO, Molidustat provides a more physiological correction of anemia and avoids risks of hypertension and excessive EPO exposure (TCEP Hydrochloride Article), extending the comparative analysis from America Peptide by highlighting translational outcomes. Ongoing clinical trials continue to evaluate its efficacy and safety for CKD-associated anemia (APExBIO).

Common Pitfalls or Misconceptions

• Molidustat is not effective in anemia unrelated to impaired EPO expression (e.g., hemolytic or nutritional anemia).
• It does not directly treat underlying kidney damage; it targets anemia secondary to CKD.
• In vitro potency measurements can vary with assay 2-oxoglutarate concentrations; standardize conditions for comparability.
• High concentrations in non-recommended solvents (e.g., water, ethanol) can cause precipitation and loss of activity.
• Not indicated for acute correction of severe anemia or for short-term EPO spikes.

Workflow Integration & Parameters

Molidustat is supplied as a solid (molecular weight 314.3; C₁₃H₁₄N₈O₂) by APExBIO. It should be stored at -20°C. Solutions in DMF (≥5.68 mg/mL) are recommended for short-term use only (APExBIO). For in vitro studies, maintain buffer at pH 7.4 and control 2-oxoglutarate concentration for consistent readouts (America Peptide). For in vivo models, dosing should be titrated to achieve target hemoglobin without exceeding physiological EPO levels. See HIF-1.com’s review for solubility and workflow tips, which this article updates with new clinical data. For further guidance on cell-based assay optimization, refer to Sulfo-Cy3-NHS-Ester.com, noting that this dossier provides expanded context on in vivo translation.

Conclusion & Outlook

Molidustat (BAY85-3934) provides a validated, mechanism-based approach for stimulating endogenous EPO in renal anemia via selective HIF-PH inhibition. Its favorable safety and efficacy profile in preclinical models, combined with robust workflow compatibility, support its continued development in translational and clinical anemia research. As evidence accumulates, Molidustat is positioned to be a cornerstone reagent for studies of hypoxia signaling and erythropoiesis.